Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review

International Journal of Urology

Volumn 22, Issue 1, 2015, Pages 22-32

  Cantiello, Francesco ^a   Cicione, Antonio ^a   Salonia, Andrea ^a,b   Autorino, Riccardo ^c   De Nunzio, Cosimo ^d   Briganti, Alberto ^a,b   Gandaglia, Giorgio ^b   Dell'Oglio, Paolo ^b   Capogrosso, Paolo ^b   Damiano, Rocco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c LERNER RESEARCH INSTITUTE   (United States)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bladder cancer; Diabetes mellitus; Metabolic syndrome; Obesity; Pathological outcomes

Indexed keywords

BLADDER CANCER; CANCER PROGNOSIS; CANCER RISK; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; BLADDER TUMOR; BODY MASS; COMPLICATION; DISEASE COURSE; INSULIN RESISTANCE; PROGNOSIS; RISK FACTOR;

BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PROGNOSIS; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84920872336     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12644     Document Type: Review

References (60)

1. Kassi E, Pervanidou P, Kaltsas G, Chrousos G, Metabolic syndrome: definitions and controversies. BMC Med. 2011; 9: 48-60.
2. Esposito K, Chiodini P, Colao A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35: 2402-2411.
3. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am. J. Pathol. 2006; 16: 1505-1522.
4. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 2012; 6: 560-570.
5. Babjuk M, Burger M, Zigeuner R etal. European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 2013; 64: 639-653.
6. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 2010; 8: 336-341.
7. Häggström C, Stocks T, Rapp K etal. Metabolic syndrome and risk of bladder cancer: prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int. J. Cancer 2011; 128: 1890-1898.
8. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur. J. Cancer 2008; 44: 293-297.
9. Cantiello F, Cicione A, Autorino R etal. Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. World J. Urol. 2014; 32: 559-564.
10. Wang Y, Beydoun MA. The obesity epidemic in the United States-gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol. Rev. 2007; 29: 26-28.
11. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200.
12. Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol. Oncol. 2011; 29: 476-486.
13. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int. J. Cancer 2007; 120: 140-146.
14. Koebnick C, Michaud D, Moore SC etal. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 1214-1221.
15. Larsson SC, Andersson SO, Johansson JE, Wolk A. Diabetes mellitus, body size and bladder cancer risk in a prospective study of Swedish men. Eur. J. Cancer 2008; 44: 2655-2660.
16. Qin Q, Xu X, Wang X, Zheng XY. Obesity and Risk of Bladder Cancer: a Meta-analysis of Cohort Studies. Asian Pac. J. Cancer Prev. 2013; 14: 3117-3121.
17. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003; 348: 1625-1638.
18. Batty GD, Shipley MJ, Jarrett RJ, Breeze E, Marmot MG, Smith GD. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int. J. Obes. 2005; 29: 1267-1274.
19. Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J. Urol. 2005; 173: 1513-1517.
20. Maurer T, Maurer J, Retz M etal. Influence of body mass index on operability, morbidity and disease outcome following radical cystectomy. Urol. Int. 2009; 82: 432-439.
21. Chromecki TF, Cha EK, Fajkovic H etal. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013; 111: 249-255.
22. Kluth LA, Xylinas E, Crivelli JJ etal. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J. Urol. 2013; 190: 480-486.
23. Wyszynski A, Tanyos SA, Rees JR etal. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. Cancer 2014; 120: 408-414.
24. Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet 2010; 375: 2201-2202.
25. Xu X, Wu J, Mao Y etal. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One 2013; 8: e58079.
26. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am. J. Epidemiol. 2004; 159: 1160-1167.
27. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012; 35: 1835-1844.
28. Tseng CH, Chong CK, Tseng CP, Chan TT. Age-related risk of mortality from bladder cancer in diabetic patients: a 12-year follow-up of a national cohort in Taiwan. Ann. Med. 2009; 41: 371-379.
29. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
30. Lam EK. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Ann. Oncol. 2011; 22: 730-738.
31. Seshasai SR, Kaptoge S, Thompson A etal. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011; 364: 829-841.
32. Liu X, Ji J, Sundquist K, Sundquist J, Hemminki K. The impact of type 2 diabetes mellitus on cancer-specific survival: a follow-up study in Sweden. Cancer 2012; 118: 1353-1361.
33. Zhu Z, Zhang X, Shen Z etal. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One 2013; 8: e56662.
34. Jalving M, Gietema JA, Lefrandt JD etal. Metformin: taking away the candy for cancer? Eur. J. Cancer 2010; 46: 2369-2380.
35. Zhang T, Guo P, Zhang Y etal. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int. J. Mol. Sci. 2013; 14: 24603-24618.
36. Rieken M, Xylinas E, Kluth L etal. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. Urol. Oncol. 2014; 32: 49.e7-14.
37. Rieken M, Xylinas E, Kluth L etal. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 2013; 112: 1105-1112.
38. Hwang EC, Kim YJ, Hwang IS etal. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int. J. Urol. 2011; 18: 769-776.
39. Yang DR, Lin SJ, Ding XF etal. Higher expression of peroxisome proliferator-activated receptor γ or its activation by agonist thiazolidinedione-rosiglitazone promotes bladder cancer cell migration and invasion. Urology 2013; 81: 1109.e1-11096.
40. Turn RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of Bladder Cancer: a Systematic Review and Meta-analysis. Br. J. Clin. Pharmacol. 2014; 78: 258-273.
41. Ornskov D, Nexo E, Sorensen BS. Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system. FEBS J. 2006; 273: 5479-5489.
42. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res. Clin. Pract. 2011; 91: 177-182.
43. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011; 117: 1552-1556.
44. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int. J. Cancer 2013; 132: 2186-2191.
45. Tseng CH. Human insulin does not increase bladder cancer risk. PLoS One 2013; 9: e86517.
46. Hamet P. Cancer and hypertension. Hypertension 1996; 28: 321-324.
47. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am. J. Med. 2002; 112: 479-486.
48. Batty GD, Shipley MJ, Marmot MG, Davey Smith G, Whitehall Study. Blood pressure and site-specific cancer mortality: evidence from the original Whitehall study. Br. J. Cancer 2003; 89: 1243-1247.
49. Stocks T, Van Hemelrijck M, Manjer J etal. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 2012; 59: 802-810.
50. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11: 627-636.
51. Bangalore S, Kumar S, Kjeldsen SE etal. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol. 2011; 12: 65-72.
52. Jiang X, Castelao JE, Yuan JM etal. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis 2010; 31: 1964-1971.
53. Strohmaier S, Edlinger M, Manjer J etal. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 2013; 8: e54242.
54. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer 2011; 11: 409.
55. Zhang XL, Geng J, Zhang XP etal. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 2013; 24: 769-776.
56. da Silva RD, Xylinas E, Kluth L etal. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J. Urol. 2013; 190: 487-492.
57. Crivelli JJ, Xylinas E, Kluth LA etal. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int. 2013; 112: e4-10.
58. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J. Urol. 2008; 180: 1297-1300.
59. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N. Eng. J. Med. 2007; 356: 1276-1277.
60. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N. Eng. J. Med. 2006; 355: 2705-2707.